Table 2. Comparison of Tirzepatide vs GLP-1 RA for Primary and Secondary Outcomes.
Outcome | No. of patients with outcome | AHR (95% CI) | P value | E-value (E-value for the upper limit of CI) | |
---|---|---|---|---|---|
Tirzepatide (n = 14 832) | GLP-1 RA (n = 14 832) | ||||
Primary outcome | |||||
All-cause mortality | 95 | 166 | 0.58 (0.45-0.75)a | <.001b | 2.82 (1.99) |
Secondary outcomes | |||||
MACEs | 472 | 589 | 0.80 (0.71-0.91)a | <.001b | 1.79 (1.44) |
MACE and all-cause mortality | 543 | 721 | 0.76 (0.68-0.84)a | <.001b | 1.98 (1.65) |
Kidney events | 53 | 102 | 0.52 (0.37-0.73)a | <.001b | 3.24 (2.09) |
Acute kidney injury | 506 | 652 | 0.78 (0.70-0.88)a | <.001b | 1.87 (1.53) |
MAKEs | 129 | 241 | 0.54 (0.44-0.67)a | <.001b | 3.11 (2.35) |
Abbreviations: AHR, adjusted hazard ratio; GLP-1 RA, glucagon-like peptide 1 receptor agonist; MACE, major adverse cardiovascular event; MAKE, major adverse kidney event.
Proportionality (Schoenfeld test P > .05).
Bonferroni-corrected α = .0083.